RALEIGH, N.C., Aug. 9, 2013 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the appointment of Kathryn F. Twiddy as vice president, general counsel and corporate secretary.
"Kathy's extensive legal experience navigating complex corporate and technology transactions will provide the heightened level of insight and direction LipoScience needs as we continue to grow our product offerings in the diagnostics market," said Bob Greczyn, interim chief executive officer, LipoScience, Inc. "Her experience in corporate governance and compliance with healthcare law will prove invaluable to this position. We are fortunate to have Kathy as a member of our leadership team."
Ms. Twiddy joined LipoScience as vice president, general counsel and corporate secretary from M*Modal, Inc., a leading provider of clinical documentation solutions and unstructured data analytics. She has held a number of senior executive roles throughout her career, including vice president and senior associate general counsel for Quintiles Transnational Corp., and general counsel and corporate secretary of Misys Healthcare Systems. She has over 20 years of law firm and in-house practice in the technology and life sciences industries, including three years as a partner with the firm of Kilpatrick Stockton, LLP (now Kilpatrick Townsend), and more than seven years with IBM Corporation. Ms. Twiddy graduated with honors from the University of North Carolina School of Law in Chapel Hill, N.C., where she also earned a bachelor's degree in journalism.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile®test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company's expectations for the future demand for its products and the factors that drive such demand. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Further information on potential factors and other risks that could affect the Company's business and operating results is included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at http://investor.liposcience.com/. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
SOURCE LipoScience, Inc.